- Beijing Tiantan’s preliminary net income for the first half of 2025 has decreased by 12.9%.
- The preliminary net income stands at 632.6 million yuan.
- Preliminary revenue is reported as 1.04 billion yuan.
- Total preliminary revenue amounts to 3.11 billion yuan.
- The company’s stock is currently in favor among analysts, with 12 buy recommendations and no holds or sells.
A look at Beijing Tiantan Biological Products Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 3 | |
| Growth | 5 | |
| Resilience | 4 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Beijing Tiantan Biological Products Corporation Limited, a company specializing in biological products, has received a strong overall outlook based on Smartkarma Smart Scores. With a Growth score of 5, the company is positioned for long-term expansion and development. This indicates positive potential for Beijing Tiantan Biological Products to grow and innovate within the industry.
Additionally, the company has demonstrated resilience with a score of 4, suggesting its ability to weather challenges and adapt to changing market conditions. While the Value and Dividend scores sit at 3, indicating a moderate valuation and dividend profile, the Momentum score of 3 implies a stable performance trend. Overall, Beijing Tiantan Biological Products shows promise for sustained growth and success in the future.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
